Clinical Advances of 225Ac-targeted Antibody & Small Molecule-based Agents & Revealing Preclinical Insights from Immune Checkpoint Combination Approaches

Time: 11:45 am
day: Day One LSC AM


  • Outlining why 225Ac is an attractive radioisotope for targeted therapy
  • Exploring clinical strategy and updates on Fusion’s antibody and small molecule programs, including FPI-2265 (a phase 2/3 study)
  • Revealing rational drug combinations for targeted alpha therapeutics